The USFDA has recently approved buprenorphine extended-release injection for treating patients with moderate-to-severe opioid use disorder (OUD). Buprenorphine is an antagonist of the kappa-opioid receptor and a partial agonist of the mu-opioid receptor. The safety and efficiency of buprenorphine in blocking the effects of opioids were determined in a behavioral pharmacology study conducted in 428 adults with moderate-to-severe OUD.
##Study## ## Dosages Two formulations: 1. Weekly injection (8, 16, 24, and 32 mg) – For patients who have commenced treatment with a single dose of transmucosal buprenorphine/who are already being treated with buprenorphine 2. Monthly injection (64, 96, and 128 mg) – For patients already being treated with buprenorphine Administration Subcutaneous injection Only HCPs should prepare and administer buprenorphine The lower strengths of weekly formulation…
